T-CURX
T-CURX develops personalized T cell therapies for cancer, leveraging a proprietary platform for improved patient outcomes.
About T-CURX
T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designed to improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care.
Company Facts
- Headquarters
- W├╝rzburg
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00001_00010
- Funding Stage
- early_stage_venture
- Total Funding
- $20,000,000
- Last Funding Type
- series_a
- Last Funding Date
- 2025-12-17
- Website
- t-curx.com
Industries & Categories
Biotechnology, Chemical, Oncology
Social Links
Canonical: https://fsome.com/organization/t-curx-86004 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.